Ratings by Jefferies (Faisal Khurshid)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/9/2026 | Summit Therapeutics plc | SMMT | Upgrade | Buy (Hold) |
17.28 (17.54) |
1.5% | Details | |
| 7/27/2026 | Monte Rosa Therapeutics | GLUE | Maintain | Buy (N/A) |
|
Details | ||
| 7/13/2026 | BeOne Medicines | ONC | Upgrade | Buy (Hold) |
302.83 (351.00) |
15.91% | Details | |
| 7/13/2026 | BeOne Medicines | ONC | Upgrade | Buy (Hold) |
302.83 (302.83) |
0% | Details | |
| 6/30/2026 | Abivax | ABVX | Upgrade | Buy (Hold) |
96.15 (119.46) |
24.24% | Details | |
| 6/2/2026 | Abivax | ABVX | Downgrade | Hold (Buy) |
132.63 (96.15) |
-27.51% | Details | |
| 5/27/2026 | PTC Therapeutics | PTCT | Upgrade | Buy (Hold) |
67.65 (67.57) |
-0.12% | Details | |
| 5/6/2026 | Immunocore Holdings | IMCR | Maintain | Hold (N/A) |
|
Details | ||
| 5/5/2026 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 5/1/2026 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 3/30/2026 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 3/30/2026 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 3/30/2026 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 3/27/2026 | Verastem | VSTM | Maintain | Buy (N/A) |
|
Details | ||
| 3/27/2026 | Monte Rosa Therapeutics | GLUE | Maintain | Buy (N/A) |
|
Details | ||
| 3/27/2026 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (N/A) |
|
Details | ||
| 3/27/2026 | 4D Molecular Therapeutics | FDMT | Maintain | Buy (N/A) |
|
Details | ||
| 3/27/2026 | PTC Therapeutics | PTCT | Downgrade | Hold (Buy) |
67.00 (67.65) |
0.97% | Details | |
| 3/23/2026 | Immunocore Holdings | IMCR | Maintain | Hold (N/A) |
|
Details | ||
| 3/23/2026 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 3/16/2026 | Cogent | COGT | New Coverage | Buy (N/A) |
34.00 (34.18) |
0.53% | Details | |
| 3/16/2026 | Revolution | RVMD | New Coverage | Buy (N/A) |
94.86 (207.68) |
118.93% | Details | |
| 3/16/2026 | Insmed | INSM | New Coverage | Buy (N/A) |
139.50 (128.80) |
-7.67% | Details | |
| 3/16/2026 | Abivax | ABVX | New Coverage | Buy (N/A) |
116.98 (132.63) |
13.38% | Details | |
| 3/16/2026 | BeOne Medicines | ONC | Downgrade | Hold (Buy) |
285.30 (302.83) |
6.14% | Details | |
| 3/16/2026 | Alnylam Pharmaceuticals | ALNY | Downgrade | Hold (Buy) |
317.23 (258.00) |
-18.67% | Details | |
| 3/16/2026 | Design Therapeutics Inc | DSGN | New Coverage | Buy (N/A) |
10.02 (15.02) |
49.9% | Details | |
| 3/16/2026 | Immunocore Holdings | IMCR | Downgrade | Hold (Buy) |
31.04 (34.47) |
11.05% | Details | |
| 3/16/2026 | Incyte | INCY | Downgrade | Hold (Buy) |
92.03 (126.01) |
36.92% | Details | |
| 3/16/2026 | Summit Therapeutics plc | SMMT | Downgrade | Hold (Buy) |
15.46 (17.28) |
11.77% | Details |
